XNYS
TDOC
Market cap1.01bUSD
Oct 08, Last price
5.54USD
1D
-0.36%
1Q
-40.30%
Jan 2017
-66.42%
IPO
-80.21%
Name
Teladoc Health Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
Key people
Charles Divita
Chief Executive Officer, Director · since 2024
Kelly Bliss
President, U.S. Group Health · since 2024
Fernando Madeira
President of BetterHelp · since 2024
Carlos Nueno
President, International · since 2024
Adam Vandervoort
Chief Legal Officer, Secretary · since 2015
J. Eric Evans
Independent Director · since 2023
Independent Director · since 2020
Catherine Jacobson
Independent Director · since 2020
Thomas Mckinley
Independent Director · since 2009
Kenneth Paulus
Independent Director · since 2017
David Shedlarz
Independent Director · since 2016
Mark Smith
Independent Director · since 2018
David Snow
Independent Chairman of the Board · since 2014
Legal address
c/o Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
2 Manhattanville Road
Suite 203
Purchase
Harrison, NY 10577
US
Suite 203
Purchase
Harrison, NY 10577
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||